1681·6] million cases), migraine (958·8 [872·1 to 1055·6] million), and medication overuse headache (58·5 [50·8 to 67·4] million). The highest burden of communicable neurological diseases and epilepsy occurred in the lowest socioeconomic regions of the world, commensurate with poor access to sanitation, vaccines, antibiotics, and other medicines, and incidence of meningitis was highest in western subSaharan Africa-the so-called meningitis belt. However, worldwide there was actually an overall decrease in communicable neurological disorders from 1990 to 2015. As long as neurological infections due to pathogens such as Zika and West Nile viruses and increasing antimicrobial resistance can be controlled, this downward trend in communicable neurological diseases is promising. However, the prevalence of and DALYs attributable to non-communicable neurological diseases increased because of the growing and ageing global population. In particular, Alzheimer's disease and other dementias had increases in prevalence and mortality, especially in some high-income regions.
Notably, although overall age-standardised DALYs, and deaths from all neurological disorders decreased between 1990 and 2015, the number of people with neurological diseases increased substantially, with the number of deaths from neurological disorders increasing by 36·7%, and the number of DALYs by 7·4%. Neurological diseases that more commonly occur in elderly people, such as Alzheimer's disease and other dementias, Parkinson's disease, and neurological cancers, are probably driving these overall neurological disease indices. The findings from Feigin, Vos, and coauthors' study suggest that the absolute number of people affected by (or dying from) neurological disease will continue to increase as the global population continues to grow and age. This trend could be augmented by the increasing incidence of stroke in lowincome countries, despite the success in curbing stroke in high-income countries.
The GBD 2015 Neurological Disorders Collaborator Group present a tremendous amount of data in a concise format, but three overriding points emerge from their assessment. First, the reduction in the burden of communicable neurological diseases in high-income and middle-income countries emphasises the need to
